Amphastar Pharmaceuticals (AMPH) Return on Capital Employed (2014 - 2026)

Amphastar Pharmaceuticals' Return on Capital Employed history runs 13 years deep, the most recent figure standing at 7.92% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 596.0% year-over-year to 7.92% in Q1 2026; TTM through Mar 2026 was 7.92%, a 596.0% decrease from a year earlier, with the FY2025 full-year figure at 9.71%, down 526.0% from the prior year.
• Return on Capital Employed fell to 7.92% in Q1 2026 per AMPH's latest filing, from 9.43% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 18.29% in Q1 2023 and bottomed at 7.92% in Q1 2026.
• The 5-year median for Return on Capital Employed is 15.07% (2022), against an average of 14.32%.
• Across the five-year window, Return on Capital Employed soared 1132 bps in 2022 and sank 596 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 16.81% in 2022, then fell by 10 bps to 15.11% in 2023, then decreased by 2 bps to 14.8% in 2024, then sank by 36 bps to 9.43% in 2025, then dropped by 16 bps to 7.92% in 2026.
• Per Business Quant, the three latest AMPH Return on Capital Employed figures stand at 7.92% (Q1 2026), 9.43% (Q4 2025), and 10.44% (Q3 2025).